Biblio Discovery — Demo Discovery Service

20 results for "Lot A. Devriese"

Showing 1–20 · 0.68 seconds · RSS

  1. Journal Article

    The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis

    Sangeeta K. Bisheshar; Emma J. De Ruiter; Lot A. Devriese et al.

    OncoImmunology, Vol. 9 No. 1 · 2020 · English · DOAJ Scopus

    Background: Despite the improvement in therapeutic interventions, 5-year survival rates in Head and Neck Squamous Cell Carcinoma (HNSCC) are limited. HNSCC is an immunogenic cancer type for which molecular stratification markers are lacking. Tumor-infiltrating lymphocytes (TILs) have shown a…

  2. Journal Article

    The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis

    Emma J. de Ruiter; Marc L. Ooft; Lot A. Devriese et al.

    OncoImmunology, Vol. 6 No. 11 · 2017 · English · DOAJ Scopus

    Background – The presence of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment is associated with an improved prognosis and a better response to therapy in different types of cancer. In this systematic review and meta-analysis, we investigated the prognostic value of T cells in…

  3. Journal Article

    First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer

    Thomas J. W. Klein Nulent; Robert J. J. van Es; Stefan M. Willems et al.

    EJNMMI Research, Vol. 11 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Background Advanced salivary gland cancers become difficult to treat when they are technically irresectable and radiotherapy limits are exceeded. There is also an unmet need to improve palliative systemic therapy. Salivary glands depict the Prostate-Specific Membrane Antigen (PSMA) on…

  4. Journal Article Full text

    Agreement and Reliability of Cone-Beam Computed Tomography Scans to Assess Skeletal Muscle Mass During Radiotherapy in Patients with Head and Neck Squamous Cell Carcinoma

    Anouk W. M. A. Schaeffers; Eline R. du Pon; Ernst J. Smid et al.

    Applied Sciences, Vol. 16 No. 8 · 2026 · English · DOAJ Scopus

    Background: Monitoring skeletal muscle mass (SMM) during radiotherapy (RT) is important, as SMM loss is associated with poorer clinical outcomes. Cone-beam CT (CBCT), acquired before each RT fraction, offers the potential to track the lumbar skeletal muscle index (LSMI) over time. However, CBCT has…

  5. Journal Article

    Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands

    Maartje W. Rohaan; Marleen L. Duizer; Lot A. Devriese et al.

    EJC Skin Cancer, Vol. 1 · 2023 · English · DOAJ Scopus

    Background: Cutaneous squamous cell carcinoma (CSCC) is the second most common cutaneous malignancy and patients with advanced disease have a poor prognosis. Phase I/II clinical studies have shown the efficacy of cemiplimab, a monoclonal anti-PD-1 antibody, for this disease. However, real-world…

  6. Journal Article Full text

    Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol

    Anouk W. M. A. Schaeffers; Lot A. Devriese; Carla H. van Gils et al.

    PLOS ONE, Vol. 18 No. 11 · 2023 · English · PLOS Scopus

    Chemoradiotherapy with cisplatin in a triweekly regimen of 100 mg/m2 body surface area, is used to treat locally advanced head and neck squamous cell carcinoma (HNSCC) with curative intent. Cisplatin dose limiting toxicity (CDLT) occurs often and impedes obtaining the planned cumulative cisplatin…

    Also available at: DOAJ, DOAJ

  7. Journal Article

    Diagnostic and Treatment-Related Challenges in Sinonasal Teratocarcinosarcoma: A Report of Three Cases

    W. F. Julius Scheurleer; Weibel W. Braunius; Bernard M. Tijink et al.

    Case Reports in Otolaryngology, Vol. 2023 · 2023 · English · DOAJ

    Background. Sinonasal teratocarcinosarcoma is a rare, aggressive malignancy located almost exclusively in the nasal cavity, paranasal sinuses, or anterior skull base. Histopathological diagnosis can be challenging due to the heterogeneous composition. Methods. Retrospective analysis of 3 patients…

  8. Journal Article

    ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study

    Marit A. C. Vermunt; Debbie G. J. Robbrecht; Lot A. Devriese et al.

    Cancer Reports, Vol. 4 No. 4 · 2021 · English · DOAJ Scopus

    Abstract Background ModraDoc006 is an oral formulation of docetaxel, which is co‐administered with the cytochrome P450 3A4 and P‐glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Weekly treatment with ModraDoc006/r had been evaluated in phase I trials in patients with different types of advanced…

  9. Journal Article Full text

    Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial

    Robert Louis Ferris; William Charles Spanos; Rom S. Leidner et al.

    Journal for ImmunoTherapy of Cancer · 2021 · English · OpenAlex Scopus

    BACKGROUND: Head and neck squamous cell carcinomas (HNSCCs) are common malignancies caused by carcinogens, including tobacco and alcohol, or infection with human papillomavirus (HPV). Immune checkpoint inhibitors targeting the programmed cell death 1 (PD-1) pathway are effective against…

    Also available at: DOAJ

  10. Journal Article

    Change of skeletal muscle mass and associated factors during radiotherapy and chemoradiotherapy in patients with head and neck squamous cell carcinoma

    Anouk W.M.A. Schaeffers; Hannah A. Scholten; Annemieke Kok et al.

    Oral Oncology Reports, Vol. 14 · 2025 · English · DOAJ Scopus

    Background and purpose: The aim is to investigate whether lumbar skeletal muscle index (LSMI) decreases during treatment of head and neck squamous cell carcinoma (HNSCC) patients, and which pre-treatment variables are associated with change. Materials and methods: The LSMI before and during…

  11. Journal Article

    The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patients

    Corine deJong; Najiba Chargi; Gerarda J.M. Herder et al.

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 13 No. 3 · 2022 · English · DOAJ Scopus

    Abstract Background Chemotherapy‐induced toxicities frequently occur in non‐small cell lung cancer (NSCLC) patients treated with platinum‐based chemotherapy. Low skeletal muscle mass (SMM) has been associated with a higher incidence of toxicities for several types of cancers and cytostatics. The…

  12. Journal Article

    Accurate detection of circulating tumor DNA using nanopore consensus sequencing

    Alessio Marcozzi; Myrthe Jager; Martin Elferink et al.

    npj Genomic Medicine, Vol. 6 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Levels of circulating tumor DNA (ctDNA) in liquid biopsies may serve as a sensitive biomarker for real-time, minimally-invasive tumor diagnostics and monitoring. However, detecting ctDNA is challenging, as much fewer than 5% of the cell-free DNA in the blood typically originates from the…

  13. Journal Article Full text

    Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial

    Suzanne Louise Topalian; Shailender Bhatia; Asim Amin et al.

    Journal of Clinical Oncology · 2020 · English · OpenAlex Scopus

    PURPOSE: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cell polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is often upregulated in MCC, and advanced metastatic MCC frequently responds to…

  14. Journal Article

    Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer

    Marshall Posner; Erminia Massarelli; Lisa Licitra et al.

    Journal for ImmunoTherapy of Cancer, Vol. 13 No. 9 · 2025 · English · DOAJ Scopus

    Background Peltopepimut-S is a therapeutic vaccine, which induces specific expansion of both CD4+helper and CD8+cytotoxic T-cells against human papillomavirus type 16 (HPV16) E6/E7 oncoproteins.Patients and methods In a randomized phase 2 trial, we evaluated the efficacy and safety of…

  15. Journal Article

    Head and Neck Cancer in Suriname: An Epidemiologic Review of Clinical and Pathologic Features of Patients Treated Between 2009 and 2021

    Sangeeta K. Bisheshar; Els T.M. Dams; Mikel Chan et al.

    JCO Global Oncology, Iss 11 (2025) · 2025 · English · DOAJ Scopus

    PURPOSEThis study investigates the incidence and clinicopathologic characteristics of head and neck cancer (HNC) in the Surinamese population, with an emphasis on the burden of human papillomavirus (HPV) and Epstein-Barr virus (EBV).METHODSHistologically confirmed HNC diagnosed between 2009 and…

  16. Journal Article

    Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolResearch in context

    Karlijn Verkerk; Birgit S. Geurts; Laurien J. Zeverijn et al.

    The Lancet Regional Health. Europe, Vol. 39 · 2024 · English · DOAJ Scopus

    Summary: Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we present RWD from PD-1 blocker cemiplimab in patients with…